Eutilex Co., Ltd.

3:15 PM - 3:30 PM (PDT), Monday, June 13, 2022
Founded in 2015 and based in Seoul, South Korea, Eutilex Co., Ltd. (Stock Code: 263050.KOSDAQ) is a clinical-stage biotechnology company focused on the research and development of innovative T cell receptor (TCR) T cell, chimeric antigen receptor (CAR) T cell, and immunomodulatory antibody therapeutics for cancer and autoimmune diseases. Eutilex is developing preclinical and clinical-stage immunotherapeutics using its three in-house platform technologies. The pipeline consists of first- and best-in-class immuno-oncology antibodies; viral, shared, and neo-antigen-specific TCR-T cell; and next generation CAR-T and U-CAR-T cell therapeutics. Eutilex is positioning itself to be a leading biotechnology company in the anti-tumor immunotherapy markets through its ground-breaking technical innovation and continues to push for early commercialization by developing its immuno-oncology pipelines in collaboration with a number of biotechnology companies and research institutes, globally.
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
EU101: anti 4-1BB monoclonal therapeutic antibody
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
At least 4
Chief Financial Officer